The manufacturer of Ozempic is testing amycretin, an experimental weight-loss pill that appears to help people quickly shed pounds.

Ozempic and Wegovy (semaglutide) promoted the loss of 10% or more body weight in 61% of people being treated for obesity and 23% being treated for diabetes after a year on the drugs, researchers reported Sept. 13 in the journal JAMA Network Open.

On that note, Terns Pharmaceuticals ( TERN -5.84%) is a biotech developing weight loss therapies that's worth investing $1,000 in today, provided that you're patient enough to hold it for at least a handful of years so that it can (hopefully) get its first product approved for sale. Here's why it's a compelling biotech stock pick.

The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis.

Injectable prescription drugs that reduce appetite — like Ozempic, Saxenda and Mounjaro — have skyrocketed in popularity in recent years.

Obesity is a complex chronic disease in which abnormal or excessive accumulation of body fat impairs health, writes Dr Jason Seewoodhary.